Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MAPS Trial: Matrix And Platinum Science (MAPS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stryker Neurovascular
ClinicalTrials.gov Identifier:
NCT00396981
First received: November 6, 2006
Last updated: January 19, 2016
Last verified: January 2016
Results First Received: February 7, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Intracranial Aneurysms
Interventions: Device: Matrix 2® coils for endovascular aneurysm occlusion
Device: GDC® coils for endovascular aneurysm occlusion

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Matrix 2® Coils for Endovascular Aneurysm Occlusion

Matrix 2® Coils for endovascular aneurysm occlusion

Matrix 2® coils for endovascular aneurysm occlusion : endovascular aneurysm occlusion coil

GDC® Coils for Endovascular Aneurysm Occlusion

GDC® Coils for endovascular aneurysm occlusion

GDC® coils for endovascular aneurysm occlusion : endovascular aneurysm occlusion coil

Total Total of all reporting groups

Baseline Measures
   Matrix 2® Coils for Endovascular Aneurysm Occlusion   GDC® Coils for Endovascular Aneurysm Occlusion   Total 
Overall Participants Analyzed 
[Units: Participants]
 311   315   626 
Age 
[Units: Years]
Mean (Standard Deviation)
 55.7  (11.6)   54.4  (13.2)   55.0  (12.5) 
Gender 
[Units: Participants]
     
Female   229   211   440 
Male   82   104   186 
Region of Enrollment 
[Units: Participants]
     
France   17   15   32 
United States   183   190   373 
Mexico   1   2   3 
Canada   16   15   31 
Spain   46   44   90 
Turkey   4   6   10 
Australia   1   3   4 
Norway   6   5   11 
Germany   13   10   23 
China   7   9   16 
United Kingdom   17   16   33 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Target Aneurysm Recurrence (TAR) Defined as Clinically Relevant Recurrence Resulting in Target Aneurysm Reintervention, Rupture/Re-rupture and/or Death From an Unknown Cause.   [ Time Frame: 12 months ]

2.  Secondary:   Angiographic Assessments   [ Time Frame: Reintervention or 12 months ]

3.  Secondary:   Neurological Assessments   [ Time Frame: 12 months ]

4.  Secondary:   Technical Procedure Success   [ Time Frame: Post-procedure ]

5.  Secondary:   Target Aneurysm Recurrence   [ Time Frame: 2 years ]

6.  Secondary:   Target Aneurysm Recurrence   [ Time Frame: 3 years ]

7.  Secondary:   Target Aneurysm Recurrence   [ Time Frame: 5 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information